Refractory Acute Myeloid Leukemia (AML)
Oncology
Prevalence
6.0 / 100K
Incidence
4.3 / 100K/yr
6 drugs in development·5 companies·0 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| komzifti | Kura Oncology, Inc. (KURA) |
Phase 2(1)
| Drug | Company |
|---|---|
| rtx-240 | Rubius Therapeutics, Inc. (RUBY) |
Phase 1(2)
Preclinical(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Refractory Acute Myeloid Leukemia (AML)?
BioSniper tracks 6 drugs in development for Refractory Acute Myeloid Leukemia (AML) across 5 companies.
What is the prevalence of Refractory Acute Myeloid Leukemia (AML)?
The estimated prevalence of Refractory Acute Myeloid Leukemia (AML) is approximately 6.0 per 100,000 population.
Deep-dive into Refractory Acute Myeloid Leukemia (AML)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis